Endothelin receptors as a potential therapeutic target in the treatment of cardiovascular disease: Rationale for selective antagonism of the ET(A) subtype

Drug News and Perspectives

Volumn 9, Issue 6, 1996, Pages 348-350

  Webb, M L ^a   Liu, E C K ^a   Aversa, C R ^a   Spinale, F G ^a   Russell, M E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN;

CARDIOVASCULAR DISEASE; HUMAN; RECEPTOR BLOCKING; SHORT SURVEY;

EID: 0030058506     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (0)